The ACE ImmunoID Platform combines the ACE Cancer Exome and ACE Cancer Transcriptome assays to enable broad tumor immunogenomic characterization.
ACE ImmunoID includes comprehensive bioinformatics reporting, provided for both DNA and RNA, utilizing our robust somatic pipelines. The platform can be further customized based on your unique research and project needs by using NeoantigenID to enable neoantigen identification, and/or ImmunogenomicsID for the assessment of tumor immunogenomics in critical genes, providing information including expression, variant effect impact, and DNA/RNA allelic fractions.
| Technical Details | |
|---|---|
| Assay Configuration | ACE Cancer Exome and ACE Cancer Transcriptome |
| Sequencing depth | DNA: ≥200x (tumor)/≥70x (normal) RNA: 100M total reads (tumor) |
| Sensitivity* | 99% SNV >94% indel |
| Sample source | FFPE, fresh frozen, fine needle aspirates, PBMCs |
| Analysis configuration | Paired tumor and normal only |
*20% Mean Allelic Frequency
